ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Agios Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 115.68%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 3 consecutive quarters
- NET PROFIT(HY) Higher at USD -199.81 MM
- NET SALES(Q) Highest at USD 44.74 MM
- OPERATING PROFIT MARGIN(Q) Highest at -244.05 %
2
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Agios Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Agios Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Agios Pharmaceuticals, Inc.
-12.92%
-0.41
79.10%
S&P 500
21.51%
1.63
13.19%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-23.27%
EBIT Growth (5y)
-12.72%
EBIT to Interest (avg)
-324.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.03
Tax Ratio
6.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
9.08%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.83
EV to EBIT
-2.87
EV to EBITDA
-2.90
EV to Capital Employed
3.79
EV to Sales
25.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-132.22%
ROE (Latest)
-34.60%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
NET PROFIT(HY)
Higher at USD -199.81 MM
NET SALES(Q)
Highest at USD 44.74 MM
OPERATING PROFIT MARGIN(Q)
Highest at -244.05 %
RAW MATERIAL COST(Y)
Fallen by -18.69% (YoY
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 6.74 times
Here's what is working for Agios Pharmaceuticals, Inc.
Net Sales
At USD 44.74 MM has Grown at 170.98%
over average net sales of the previous four periods of USD 16.51 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 44.74 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -244.05 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Higher at USD -199.81 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -18.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Agios Pharmaceuticals, Inc.
Debtors Turnover Ratio
Lowest at 6.74 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
